Trial · NCT03292146
Adverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 16 of 16
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | constipation | Gastrointestinal disorders | Denosumab (0-12 months) followed by alendronate (12-24 months) | 3 | 20 | 4 |
| other | constipation | Gastrointestinal disorders | Placebo (0-12 months) followed by alendronate (12-24 months) | 0 | 10 | 0 |
| other | COVID-19 | Infections and infestations | Denosumab (0-12 months) followed by alendronate (12-24 months) | 1 | 20 | 1 |
| other | COVID-19 | Infections and infestations | Placebo (0-12 months) followed by alendronate (12-24 months) | 1 | 10 | 1 |
| other | nausea/stomach pain/bloating | Gastrointestinal disorders | Denosumab (0-12 months) followed by alendronate (12-24 months) | 1 | 20 | 2 |
| other | nausea/stomach pain/bloating | Gastrointestinal disorders | Placebo (0-12 months) followed by alendronate (12-24 months) | 0 | 10 | 0 |
| other | bone fracture | Injury, poisoning and procedural complications | Denosumab (0-12 months) followed by alendronate (12-24 months) | 1 | 20 | 1 |
| other | bone fracture | Injury, poisoning and procedural complications | Placebo (0-12 months) followed by alendronate (12-24 months) | 1 | 10 | 1 |
| other | Keratitis | Infections and infestations | Denosumab (0-12 months) followed by alendronate (12-24 months) | 1 | 20 | 1 |
| other | Keratitis | Infections and infestations | Placebo (0-12 months) followed by alendronate (12-24 months) | 0 | 10 | 0 |
| other | Gallbladder biliary dyskinesia | Gastrointestinal disorders | Denosumab (0-12 months) followed by alendronate (12-24 months) | 0 | 20 | 0 |
| other | Gallbladder biliary dyskinesia | Gastrointestinal disorders | Placebo (0-12 months) followed by alendronate (12-24 months) | 1 | 10 | 1 |
| other | C. difficile | Infections and infestations | Denosumab (0-12 months) followed by alendronate (12-24 months) | 1 | 20 | 1 |
| other | C. difficile | Infections and infestations | Placebo (0-12 months) followed by alendronate (12-24 months) | 0 | 10 | 0 |
| other | Disc degeneration and herniation | Injury, poisoning and procedural complications | Denosumab (0-12 months) followed by alendronate (12-24 months) | 1 | 20 | 1 |
| other | Disc degeneration and herniation | Injury, poisoning and procedural complications | Placebo (0-12 months) followed by alendronate (12-24 months) | 0 | 10 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03292146/events